3 May 2016
EMA/CAT/318967/2016
Procedure Management and Committees Support Division

CAT monthly report of application procedures, guidelines and related documents on advanced therapies

April 2016 meeting

The Committee for Advanced Therapies (CAT) held its 81st CAT meeting on 20-21 April 2016.

The CAT Monthly Report includes statistical data on CAT scientific recommendations on Advanced Therapy Medicinal Product (ATMP) classification, certifications, initial evaluations, CAT contributions to Scientific Advice and Paediatric Investigation Plans, as well as variations, line extensions, renewals.

ATMP Certification procedure

At its April meeting, CAT adopted a positive opinion on the certification application for an ATMP developed by a micro, small and medium-sized enterprise (SME). The ATMP concerned by this certification application is a tissue engineered product composed of autologous mesenchymal stem cells committed to the cardiovascular lineage, intended for the treatment of patients with chronic heart failure secondary to ischemic cardiomyopathy. The certification for this product related to the non-clinical data. CAT certified in April 2014 the quality data for this product.

Scientific recommendation on advanced therapy product classification

Further to consultation with the European Commission, the CAT finalised four scientific recommendations on the classification of advanced therapy medicinal products.

The following products were classified as gene therapy medicinal products:

- Haematopoietic stem and progenitor cells genetically modified with zinc finger nucleases to disrupt the erythroid enhancer of the gene encoding for human transcription factor BCL11A. This product is intended for the treatment of ß-thalassemia.

- DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human tumour necrosis factor alfa p55 receptor linked to the human immunoglobulin G1 Fc domain. This product is intended for the treatment of refractory chronic non-infectious uveitis.

The following products were classified as somatic cell therapy medicinal products:

- Autologous ex vivo expanded polyclonal $CD4^{+}CD25^{+}CD127^{lo/-}FOXP3^{+}$ regulatory T cells, intended for the treatment of type 1 diabetes mellitus.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

- Autologous human bone marrow mononuclear cells, intended for the treatment of type 2 diabetes mellitus.

Additionally, CAT was unable to conclude on the classification of two products, as it was unclear if the intended use could be considered a medicinal indication:

- Autologous stromal vascular fraction, intended to be used as an autologous lipofiller.
- Autologous adipose-derived regenerative cells encapsulated in carboxymethylcellulose intended to be used as autologous dermal filler.

Clarity with regards to the fulfilment of the definition of a medicinal product is a prerequisite for ATMP classification and the classification as medicinal product is outside of the remit of the CAT. The applicants of these products were advised to contact the national competent authorities for the classification of their products.

CAT received 4 new ATMP classification requests for which a scientific recommendation will be delivered within 60 days (active review time).

Further information on the ATMP classification procedure can be found at:

European Medicines Agency - ATMP classification

Organisational, regulatory and methodological matters

- CAT discussed how they could contribute to the review of eligibility request for PRIME for ATMPs.
- CAT decide to postpone the assessor training (originally scheduled for 23-24 June 2016) to a later date. This will allow CAT to dedicate its resources to other CAT workplan activities such as the Workshop on cell-based cancer immunotherapies.

Overview of product-related activities

The Committee discussed ongoing evaluation procedures for ATMPs and other related procedures as summarised in the following tables:

Initial Evaluation of Marketing Authorisation Applications (MAA) for ATMP									
	2009	**2010**	**2011**	**2012**	**2013**	**2014**	**2015**	**2016**	**Total**
Submitted MAAs	3	1	2	3	2	2	1	1	15
Positive draft Opinion	1	0	1[ii]	1[ii]	2	1	1	1	8 Corresponding to 7 ATMPs
Negative draft opinions	1[i]	0	1[ii]	0	0	0	2[*]	0	4
Withdrawals	1	1[i]	0	0	2	0	0	0	4
Ongoing MAAs									3

[i] Same product (Cerepro)
[ii] Same product (Glybera)
[*] CAT adopted two negative draft opinions for the same product (Heparesc)

Variations (Type II) for authorised ATMP									
	2009	2010	2011	2012	2013	2014	2015	2016	Total
Positive draft Opinion	0	0	1	1	9	4	3	3	21

Scientific recommendation on advanced therapy classification									
	2009	2010	2011	2012	2013	2014	2015	2016	Total
Submitted	22	19	12	22	20	28	61	32	216
Adopted	12	27	12	16	23	29	31	49	199

Certification of quality and non-clinical data for small and medium-sized enterprises developing ATMPs									
	2009	2010	2011	2012	2013	2014	2015	2016	Total
Submitted	1	0	0	1	3	1	1	1	8
Adopted	0	1	0	1	1	2	1	1	7

Scientific advice procedure for ATMPs									
	2009	2010	2011	2012	2013	2014	2015	2016	Total
Discussed*	25	30	36	31	36	48	63	26	295
Number of procedures	17	19	21	19	23	33	39	23	194

* Most scientific advices for ATMPs are discussed by the CAT at 2 time points during the SA procedure

Paediatric Investigation Plans (PIP) for ATMPs									
	2009	2010	2011	2012	2013	2014	2015	2016	Total
Discussed*	4	7	6	9	7	7	3	2	45

* PIPs for ATMPs are discussed by the CAT once or twice during the procedure

Upcoming meetings following the March 2016 CAT meeting

The 82nd meeting of the CAT will be held on 18-20 May 2016.

NOTE:

1. This Monthly Report, the Agenda of this meeting, the Minutes of the previous CAT meeting and other documents can be found on the internet at the following location: European Medicines Agency - Committee meeting reports - CAT: Committee meeting reports

2. Specific information related to ATMPs and the activities of the CAT (role, responsibilities and composition) can be found at: European Medicines Agency - CAT - Committee for Advanced Therapies (CAT)

Sheila Kennedy
Head of Committees Secretariat Service
Tel.: (+44-20) 3660 8508
Fax: (+44-20) 3660 5520
AdvancedTherapies@ema.europa.eu